• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心力衰竭患者高钾血症的风险计算

Risk calculation for hyperkalaemia in heart failure patients.

作者信息

Vereijken T L J, Bellersen L, Groenewoud J M M, Knubben L, Baltussen L, Kramers C

机构信息

Department of Pharmacology-Toxicology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.

出版信息

Neth J Med. 2007 Jun;65(6):208-11.

PMID:17587647
Abstract

BACKGROUND

We aimed to develop a model to estimate the risk of hyperkalaemia in patients treated for heart failure in a tertiary reference hospital and to identify precipitating factors.

METHODS

125 congestive heart failure (CHF) patients were studied retrospectively. Thirty of these patients developed episodes of hyperkalaemia (K>or=5.5 mmol/l). Both groups were compared for possible risk factors for hyperkalaemia (age, glomerular filtration rate (GFR), New York Heart Association (NYHA) class, diabetes mellitus (DM), ejection fraction and medication use (ACE inhibitors, angiotensin receptor blockers, aldosterone antagonists).

RESULTS

On multivariate logistic regression analysis DM (OR 2.9, 95% CI=1.05 to 8.3, p=0.041), GFR<45 ml/min (OR 4.1, 95% CI=1.6 to 10.5. p=0.004) and NYHA class III-IV (OR 2.4, 95% CI=0.9 to 6.3, p=0.086) were independently associated with hyperkalaemia, whereas age, ejection fraction and medication sort and dose were not. Of the episodes of hyperkalaemia, 38% were precipitated by periods of dehydration (diarrhoea, fever) or change of medication.

CONCLUSION

We identified kidney function, diabetes mellitus and heart failure class as independent risk factors of hyperkalaemia. The majority of the hyperkalaemic episodes develop without a precipitating factor. This implies that heart failure patients in a tertiary reference hospital should be very closely monitored to minimize the risk for hyperkalaemia.

摘要

背景

我们旨在建立一个模型,以估计在一家三级转诊医院接受心力衰竭治疗的患者发生高钾血症的风险,并确定诱发因素。

方法

对125例充血性心力衰竭(CHF)患者进行回顾性研究。其中30例患者发生高钾血症(血钾≥5.5 mmol/L)。比较两组患者高钾血症的可能危险因素(年龄、肾小球滤过率(GFR)、纽约心脏协会(NYHA)分级、糖尿病(DM)、射血分数和药物使用情况(血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂、醛固酮拮抗剂))。

结果

多因素逻辑回归分析显示,糖尿病(比值比[OR]2.9,95%置信区间[CI]=1.05至8.3,P=0.041)、肾小球滤过率<45 ml/min(OR 4.1,95%CI=1.6至10.5,P=0.004)和NYHA III-IV级(OR 2.4,95%CI=0.9至6.3,P=0.086)与高钾血症独立相关,而年龄、射血分数以及药物种类和剂量则无关。在高钾血症发作中,38%是由脱水期(腹泻、发热)或药物变化诱发的。

结论

我们确定肾功能、糖尿病和心力衰竭分级为高钾血症的独立危险因素。大多数高钾血症发作并无诱发因素。这意味着三级转诊医院的心力衰竭患者应受到密切监测,以将高钾血症风险降至最低。

相似文献

1
Risk calculation for hyperkalaemia in heart failure patients.心力衰竭患者高钾血症的风险计算
Neth J Med. 2007 Jun;65(6):208-11.
2
Clinical factors associated with hyperkalemia in patients with congestive heart failure.充血性心力衰竭患者高钾血症的相关临床因素。
J Clin Pharm Ther. 2005 Jun;30(3):233-9. doi: 10.1111/j.1365-2710.2005.00638.x.
3
Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.蛋白尿、慢性肾病以及血管紧张素受体阻滞剂联合血管紧张素转换酶抑制剂对中重度心力衰竭患者的影响
Circulation. 2009 Oct 20;120(16):1577-84. doi: 10.1161/CIRCULATIONAHA.109.853648. Epub 2009 Oct 5.
4
[The determination of the factors impacting on in-hospital mortality in patients with acute heart failure in a tertiary referral center].[三级转诊中心急性心力衰竭患者院内死亡影响因素的确定]
Anadolu Kardiyol Derg. 2008 Aug;8(4):255-9.
5
Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism.了解心力衰竭中高钾血症的风险:醛固酮拮抗作用的作用。
Postgrad Med J. 2010 Mar;86(1013):136-42. doi: 10.1136/pgmj.2008.072058.
6
Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients.住院患者高钾血症快速发展的相关危险因素。
Drug Saf. 2007;30(1):71-80. doi: 10.2165/00002018-200730010-00007.
7
New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.醛固酮拮抗剂治疗心力衰竭的新策略及高钾血症风险
Expert Opin Drug Saf. 2005 Jul;4(4):677-88. doi: 10.1517/14740338.4.4.677.
8
Gender differences in pharmacological and clinical associates of kidney disease. A hospital-based study.
Med Princ Pract. 2008;17(2):102-7. doi: 10.1159/000112962. Epub 2008 Feb 19.
9
Risk factors for heart failure in patients with one prior myocardial infarction episode.有过一次心肌梗死发作的患者发生心力衰竭的危险因素。
Rom J Intern Med. 2008;46(3):213-21.
10
Onset time of hyperkalaemia after angiotensin receptor blocker initiation: when should we start serum potassium monitoring?血管紧张素受体阻滞剂起始后高钾血症的发作时间:我们何时应开始监测血清钾?
J Clin Pharm Ther. 2014 Feb;39(1):61-8. doi: 10.1111/jcpt.12109. Epub 2013 Nov 22.

引用本文的文献

1
[Life-threatening hyperkalemia due to a delayed hemolytic transfusion reaction].[延迟性溶血性输血反应导致的危及生命的高钾血症]
Z Gerontol Geriatr. 2021 Aug;54(5):431-433. doi: 10.1007/s00391-021-01925-4. Epub 2021 Jun 23.
2
New treatments for hyperkalaemia: clinical use in cardiology.高钾血症的新疗法:在心脏病学中的临床应用
Eur Heart J Suppl. 2019 Feb;21(Suppl A):A41-A47. doi: 10.1093/eurheartj/suy031. Epub 2019 Feb 26.
3
Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia.
帕替罗姆(一种不可吸收的交联聚合物,可降低高钾血症患者的血清钾浓度)的作用机制与药理学
J Cardiovasc Pharmacol Ther. 2016 Sep;21(5):456-65. doi: 10.1177/1074248416629549. Epub 2016 Feb 7.
4
Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy.氨基酸输注对神经内分泌肿瘤患者靶向放射性肽治疗后血钾水平的影响。
Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1675-82. doi: 10.1007/s00259-011-1826-9. Epub 2011 May 7.
5
Frequency of laboratory measurement and hyperkalaemia in hospitalised patients using serum potassium concentration increasing drugs.使用血清钾浓度升高药物的住院患者的实验室测量频率和高钾血症。
Eur J Clin Pharmacol. 2011 Sep;67(9):933-40. doi: 10.1007/s00228-011-1028-1. Epub 2011 Mar 19.